Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HUMA NASDAQ:IMDX NASDAQ:KALA NASDAQ:RNAC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHUMAHumacyte$1.16+4.1%$0.83$0.55▼$2.93$256.66M2.316.44 million shs2.50 million shsIMDXOncocyte$6.24-3.2%$4.32$2.33▼$8.51$202.94M1.63233,067 shs99,811 shsKALAKALA BIO$2.22+2.1%$7.35$2.10▼$1,030.00$41.18M-2.23116,578 shs17,397 shsRNACCartesian Therapeutics$6.86+6.4%$6.79$5.60▼$15.57$202.68M0.58179,112 shs44,349 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHUMAHumacyte+5.71%+34.50%+58.57%-4.31%-56.13%IMDXOncocyte+5.75%+15.37%+65.98%+12.00%+643,999,900.00%KALAKALA BIO-10.70%-14.23%-68.11%-89.26%-98.93%RNACCartesian Therapeutics-4.44%+5.91%-4.44%-18.25%-29.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHUMAHumacyte$1.16+4.1%$0.83$0.55▼$2.93$256.66M2.316.44 million shs2.50 million shsIMDXOncocyte$6.24-3.2%$4.32$2.33▼$8.51$202.94M1.63233,067 shs99,811 shsKALAKALA BIO$2.22+2.1%$7.35$2.10▼$1,030.00$41.18M-2.23116,578 shs17,397 shsRNACCartesian Therapeutics$6.86+6.4%$6.79$5.60▼$15.57$202.68M0.58179,112 shs44,349 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHUMAHumacyte+5.71%+34.50%+58.57%-4.31%-56.13%IMDXOncocyte+5.75%+15.37%+65.98%+12.00%+643,999,900.00%KALAKALA BIO-10.70%-14.23%-68.11%-89.26%-98.93%RNACCartesian Therapeutics-4.44%+5.91%-4.44%-18.25%-29.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHUMAHumacyte 2.75Moderate Buy$7.57555.53% UpsideIMDXOncocyte 2.00Hold$12.0092.43% UpsideKALAKALA BIO 2.00Hold$1,018.7545,893.23% UpsideRNACCartesian Therapeutics 2.67Moderate Buy$32.60375.15% UpsideCurrent Analyst Ratings BreakdownLatest KALA, HUMA, IMDX, and RNAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026RNACCartesian Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$38.005/26/2026HUMAHumacyte HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.005/26/2026RNACCartesian Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$42.00 ➝ $40.005/13/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.005/12/2026RNACCartesian Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $25.005/1/2026RNACCartesian Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$38.004/28/2026HUMAHumacyte D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.004/28/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.004/21/2026HUMAHumacyte D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.004/10/2026HUMAHumacyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026IMDXOncocyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHUMAHumacyte$2.04M125.70N/AN/A$0.05 per share23.10IMDXOncocyte$4.05M49.72N/AN/A($0.33) per share-18.90KALAKALA BION/AN/AN/AN/A$0.58 per shareN/ARNACCartesian Therapeutics$1.78M113.57N/AN/A($5.04) per share-1.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHUMAHumacyte-$40.83M-$0.57N/AN/AN/A-4,836.06%-2,914.18%-89.45%8/10/2026 (Estimated)IMDXOncocyte-$50.22M-$1.48N/AN/AN/A-2,454.64%N/A-96.96%N/AKALAKALA BIO-$26.98M-$96.14N/AN/AN/AN/A-1,336.10%-94.85%8/6/2026 (Estimated)RNACCartesian Therapeutics-$130.30M-$5.90N/AN/AN/A-8,550.65%N/A-28.25%8/6/2026 (Estimated)Latest KALA, HUMA, IMDX, and RNAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026KALAKALA BIO-$8.50-$0.14+$8.36-$0.14N/AN/A5/13/2026Q1 2026HUMAHumacyte-$0.10-$0.09+$0.01-$0.09$1.46 million$0.50 million5/13/2026Q1 2026IMDXOncocyteN/A-$0.28N/A-$0.12N/A$0.03 million4/30/2026Q1 2026RNACCartesian Therapeutics-$0.84-$1.46-$0.62-$1.46$0.22 million$0.08 million4/15/2026Q4 2025KALAKALA BIO-$8.50$0.86+$9.36$43.00N/AN/A3/27/2026Q4 2025HUMAHumacyte-$0.13-$0.13N/A-$0.13$1.35 million$0.47 million3/26/2026Q4 2025IMDXOncocyteN/A-$0.27N/A-$0.72N/A$1.14 million3/9/2026Q4 2025RNACCartesian Therapeutics-$0.82-$1.38-$0.56-$3.57$0.10 million$0.95 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHUMAHumacyteN/AN/AN/AN/AN/AIMDXOncocyteN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHUMAHumacyte5.463.933.32IMDXOncocyteN/A2.542.51KALAKALA BION/A7.917.91RNACCartesian TherapeuticsN/A7.657.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHUMAHumacyte44.71%IMDXOncocyte55.35%KALAKALA BIO24.61%RNACCartesian Therapeutics86.95%Insider OwnershipCompanyInsider OwnershipHUMAHumacyte3.10%IMDXOncocyte2.05%KALAKALA BIO2.24%RNACCartesian Therapeutics37.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHUMAHumacyte150222.02 million215.14 millionOptionableIMDXOncocyte12032.29 million31.63 millionN/AKALAKALA BIO3018.59 million18.17 millionNot OptionableRNACCartesian Therapeutics6429.38 million18.45 millionOptionableKALA, HUMA, IMDX, and RNAC HeadlinesRecent News About These CompaniesCartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027May 26 at 7:00 AM | globenewswire.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Rating of "Moderate Buy" by AnalystsMay 21, 2026 | americanbankingnews.comWe're Keeping An Eye On Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn RateMay 17, 2026 | finance.yahoo.comQ2 EPS Estimate for Cartesian Therapeutics Cut by AnalystMay 14, 2026 | marketbeat.comCartesian Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor ConferenceMay 12, 2026 | quiverquant.comQCartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 12, 2026 | globenewswire.comPrivium Fund Management B.V. Invests $1.24 Million in Cartesian Therapeutics, Inc. $RNACMay 6, 2026 | marketbeat.comCartesian Therapeutics Announces New Employment Inducement GrantsMay 4, 2026 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cartesian Therapeutics (RNAC) and Humana (HUM)May 2, 2026 | theglobeandmail.comWedbush Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)May 1, 2026 | marketbeat.comCartesian Therapeutics (NASDAQ:RNAC) Posts Quarterly Earnings ResultsApril 30, 2026 | marketbeat.comCartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue EstimatesApril 30, 2026 | zacks.comCartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateApril 30, 2026 | globenewswire.comCartesian Therapeutics (RNAC) Projected to Post Earnings on ThursdayApril 30, 2026 | marketbeat.comCartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?April 20, 2026 | zacks.comCartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference TranscriptApril 14, 2026 | seekingalpha.comCartesian Therapeutics Announces New Employment Inducement GrantsApril 2, 2026 | globenewswire.comCartesian Therapeutics (NASDAQ:RNAC) Stock, Short Interest ReportMarch 10, 2026 | benzinga.comCantor Fitzgerald upgrades Cartesian Therapeutics (RNAC)March 10, 2026 | msn.comCartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business UpdateMarch 9, 2026 | markets.businessinsider.comWhy Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 8.15%February 18, 2026 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Healthcare Stocks Set to Benefit From the One Big Beautiful BillBy Chris Markoch | May 10, 2026Tesla Ends Model S and X Era, Bets Everything on What's NextBy Sam Quirke | May 20, 20265 Robotics Stocks to Watch as Physical AI Builds MomentumBy Ryan Hasson | May 18, 2026KALA, HUMA, IMDX, and RNAC Company DescriptionsHumacyte NASDAQ:HUMA$1.16 +0.05 (+4.05%) As of 10:50 AM Eastern This is a fair market value price provided by Massive. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Oncocyte NASDAQ:IMDX$6.24 -0.20 (-3.17%) As of 10:50 AM Eastern This is a fair market value price provided by Massive. Learn more.OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.KALA BIO NASDAQ:KALA$2.22 +0.05 (+2.07%) As of 10:48 AM Eastern This is a fair market value price provided by Massive. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Cartesian Therapeutics NASDAQ:RNAC$6.86 +0.41 (+6.37%) As of 10:50 AM Eastern This is a fair market value price provided by Massive. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AutoZone's Pullback Sets Up a Long-Term Buying Opportunity AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus Powerhouse Williams-Sonoma Heading to Fresh Highs in 2026 Quantum Stocks Just Got a Lifeline—Who Benefits Most? Why BJ’s Wholesale Club Stock Could Be Ready for a Rebound 5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade Rocket Companies Turns Around, But Mortgage Risk Remains After NVIDIA, Broadcom's Earnings Are Next—Here's What to Watch Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
